水杨醛亚胺锌复合物的结构研究及抗菌、抗真菌和抗癌研究。

IF 3.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Future medicinal chemistry Pub Date : 2024-08-02 Epub Date: 2024-06-20 DOI:10.1080/17568919.2024.2363672
Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas
{"title":"水杨醛亚胺锌复合物的结构研究及抗菌、抗真菌和抗癌研究。","authors":"Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas","doi":"10.1080/17568919.2024.2363672","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Zinc salicylaldimines may act as multidrug agents.<b>Results:</b> Three zinc salicylaldimines <b>C1-C3</b> and respective ligands <b>HL<sup>1</sup></b>-<b>HL<sup>3</sup></b> were examined for antimicrobial/anticancer drug action and <b>C3</b> was structurally analyzed (tetrahedral, triclinic). Against two fungi, <b>C1</b> inhibited <i>Candida albicans</i> with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.<b>Conclusion:</b> The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1551-1560"},"PeriodicalIF":3.2000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370977/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.\",\"authors\":\"Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas\",\"doi\":\"10.1080/17568919.2024.2363672\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Zinc salicylaldimines may act as multidrug agents.<b>Results:</b> Three zinc salicylaldimines <b>C1-C3</b> and respective ligands <b>HL<sup>1</sup></b>-<b>HL<sup>3</sup></b> were examined for antimicrobial/anticancer drug action and <b>C3</b> was structurally analyzed (tetrahedral, triclinic). Against two fungi, <b>C1</b> inhibited <i>Candida albicans</i> with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.<b>Conclusion:</b> The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.</p>\",\"PeriodicalId\":12475,\"journal\":{\"name\":\"Future medicinal chemistry\",\"volume\":\" \",\"pages\":\"1551-1560\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370977/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17568919.2024.2363672\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2363672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:水杨醛亚胺锌可作为多种药物制剂。结果:研究了 C1-C3 三种水杨醛亚胺锌和各自的配体 HL1-HL3 的抗菌/抗癌作用,并对 C3 进行了结构分析(四面体、三棱体)。针对两种真菌,C1 对白色念珠菌的抑制作用为 12 毫米(对两性霉素 B 的抑制作用为 21 毫米)。在四种细菌中,两种配体对金黄色葡萄球菌和大肠杆菌的抑制作用为 9-10 毫米,但复合物对所有细菌的抑制作用为 10-14 毫米(氨苄西林为 21-26 毫米)。配体、复合物和多柔比星对癌症 MCF-7 细胞的半最大抑制浓度分别为 195.5-310.7、22.18-70.05 和 9.66 μM,对正常 BHK 细胞的半最大抑制浓度分别为 186.4-199.9、14.95-18.87 和 36.42 μM。结论尽管与标准物质相比,复配物的抗菌/抗癌活性处于中等水平,但复配物明显提高了配体的抗菌/抗癌活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.

Aim: Zinc salicylaldimines may act as multidrug agents.Results: Three zinc salicylaldimines C1-C3 and respective ligands HL1-HL3 were examined for antimicrobial/anticancer drug action and C3 was structurally analyzed (tetrahedral, triclinic). Against two fungi, C1 inhibited Candida albicans with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited Staphylococcus aureus and Escherichia coli (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.Conclusion: The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
期刊最新文献
A comprehensive insight into naphthalimides as novel structural skeleton of multitargeting promising antibiotics. A call to develop tramadol enantiomer for overcoming the tramadol crisis by reducing addiction. Advancements in PROTAC-based therapies for neurodegenerative diseases. EGFR molecular degraders: preclinical successes and the road ahead. How does machine learning augment alchemical binding free energy calculations?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1